Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …

The standard treatment of unresectable locally advanced non-small cell lung cancer (LA
NSCLC) is concurrent chemoradiotherapy. With the addition of immunotherapy, patients with …

Targeted tyrosine kinase inhibitors (TKIs) has been widely used in the treatment of
advanced non–small-cell lung cancer (NSCLC) patients with oncogene driver-mutation …

PURPOSE Identification and targeting of actionable oncogenic drivers (AODs) in advanced
non–small-cell lung cancer (NSCLC) has dramatically improved outcomes. However …

Purpose: To investigate the treatment patterns and survival outcomes in patients with
unresectable Stage III EGFR-mutated non-small cell lung cancer (NSCLC). Materials and …

Purpose: To compare survivals between unresectable stage III and stage IV EGFR-mutated
non-small cell lung cancer (NSCLC) patients receiving first-line EGFR-TKI. Materials and …

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect
patients' response to treatments [1]. Among these actionable mutations, the most clinically …

Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in EGFR-
mutated non-small-cell lung cancer patients experiencing disease progression under TKIs …

Background The study was conducted to assess differences in overall survival (OS) in
patients with non‐small cell lung cancer (NSCLC) receiving different treatment modalities of …

The present study aimed to evaluate the total progression-free survival (PFS) time of the 1st-
line chemotherapy (CHT)/2nd‑line tyrosine kinase inhibitor (TKI) and 1st‑line TKI/2nd‑line …